Navigation Links
BRAF inhibitor treatment causes melanoma cells to shift how they produce energy
Date:3/8/2013

A multi-institutional study has revealed that BRAF-positive metastatic malignant melanomas develop resistance to treatment with drugs targeting the BRAF/MEK growth pathway through a major change in metabolism. The findings, which will be published in Cancer Cell and have been released online, suggest a strategy to improve the effectiveness of currently available targeted therapies.

"We were surprised to find that melanoma cells treated with the BRAF inhibitor vemurafenib dramatically change the way they produce energy to stay alive," says David E. Fisher, MD, PhD, chief of Dermatology at Massachusetts General Hospital (MGH) and a co-corresponding author of the Cancer Cell paper. "While current BRAF inhibitor treatment is a major improvement shrinking tumors in most patients and extending survival for several months patients eventually relapse. So there is an ongoing need to improve both the magnitude and durability of these responses."

In about half the cases of malignant melanoma the most deadly form of skin cancer tumor growth is driven by mutations in the BRAF gene. Research by investigators at the MGH Cancer Center and elsewhere has shown that treatment with drugs that block BRAF activity temporarily halts tumor growth. Combining a BRAF inhibitor with a drug that targets MEK, another protein in the same growth pathway, strengthens and extends the antitumor response. The current study was designed to investigate how BRAF inhibition changes metabolic activity within melanoma cells and to find other possible treatment targets.

The most common way that cells convert glucose into energy is called oxidative phosphorylation and largely relies on the activity of the cellular structures called mitochondria. Many cancer cells use an alternative mechanism that produces the energy compound ATP without involving mitochondria. A series of experiments by the MGH team revealed that the elevated BRAF activity in BRAF-positive m
'/>"/>

Contact: Michelle Marcella
mmarcella@partners.org
617-724-2755
Massachusetts General Hospital
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
2. VyGone Inhibitor Zapper: The Brand New Solution For the Safe Treatment Of Sores, Warts and Herpes
3. Inhibitors of shuttle molecule show promise in acute leukemia
4. Leukemia inhibitory factor may be a promising target against pancreatic cancer
5. Uncommon BRAF mutation in melanoma sensitive to MEK inhibitor drug therapy
6. Preclinical data support ongoing clinical trials testing IDO inhibitors as a treatment for cancer
7. PARP inhibitors may have clinical utility in HER2-positive breast cancers
8. New mechanism of action for PARP inhibitors discovered
9. PI3-kinase and PARP inhibitor combo may offer new treatment option for triple-neg breast cancers
10. Scientists at Mainz University identify inhibitor of myelin formation in the central nervous system
11. New small molecule inhibitor could be a safe and first-line treatment for metastatic breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2014)... that can provide primary care for low-income patients ... and insurance companies while improving patient health, researchers ... suggests that health clinics that avoid costs associated ... by lowering hospital admission rates and emergency room ... Penn State Altoona. , The researchers estimated ...
(Date:4/22/2014)... DC (April 22, 2014) The International Communication ... 22-26 in Seattle, Washington. The theme of the ... means in a networked and digital society. , ... attended by over 2,200 Communication scholars representing over ... scholarly international communication conference in the world. This ...
(Date:4/22/2014)... To help rein in massive health care spending, a ... urgently find ways to incentivize pharmaceutical companies and device ... Instead of examining existing medical technologies and their use, ... affect what drugs and medical devices get created in ... health care spending with as little loss of health ...
(Date:4/22/2014)... cell lung cancer are 70 years of age or ... are not well represented in clinical trials. Therefore, the ... reach evidence based clinical recommendations. , In 2010, the ... Cancer Group along with the International Society for Geriatric ... for elderly patients with non-small cell lung cancer (NSCLC), ...
(Date:4/22/2014)... may throw tantrums like toddlers, but their total ... say, a gerbil or fox squirrel, according to ... and birds ranging from orangutans to zebra finches. ... Yale and more than two-dozen other research institutions ... evolution of self-control, defined in the study as ...
Breaking Medicine News(10 mins):Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:EORTC and SIOG update expert opinion on management of elderly patients with NSCLC 2Health News:Brain size matters when it comes to animal self-control 2Health News:Brain size matters when it comes to animal self-control 3
... A large, national multi-center study of thousands of children ... has found that most of those with normal computed ... observation. Of the more than 13,500 children included ... abnormal CT scans or MRIs and none required neurosurgical ...
... than white Americans, even when they have some ... is so, researchers at Columbia University,s Mailman School ... Medicine, surveyed African American adults with recent oral ... findings provide insights into why disparities persist even ...
... DALLAS June 16, 2011 UT Southwestern Medical ... anesthetic drug ketamine produces a fast-acting antidepressant response in ... robust effect at low doses as a fast-acting antidepressant ... "Ketamine produces a very sharp increase that ...
... esophagus may have a lower risk of esophageal cancer ... published online June 16 in the Journal of ... a premalignant condition, and patients who have it are ... signs of esophageal adenocarcinoma, the most common kind of ...
... -- The risk of cancer associated with the condition ... thought, according to a new long-term study. ... undergo routine endoscopies to screen for esophageal adenocarcinoma, a ... a long, thin tube with a camera at the ...
... Louis Children,s Hospital in the summer of 2010 near death ... lungs. Washington University physicians and surgeons at St. Louis ... his life. They collaborated to make several strategic and innovative ... artificial lung in a toddler. Their efforts are reported ...
Cached Medicine News:Health News:Hospitalizing children with normal CT scans after blunt head trauma is not necessary 2Health News:Hospitalizing children with normal CT scans after blunt head trauma is not necessary 3Health News:Why disparities in dental care persist for African-Americans even when they have insurance coverage 2Health News:Why disparities in dental care persist for African-Americans even when they have insurance coverage 3Health News:Barrett's esophagus carries lower risk of malignancy than previously reported 2Health News:Cancer Risk With Barrett's Esophagus May Be Lower Than Thought 2Health News:Washington University surgeons successfully use artificial lung in toddler 2Health News:Washington University surgeons successfully use artificial lung in toddler 3Health News:Washington University surgeons successfully use artificial lung in toddler 4
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China ... store . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) ... and policy support, China,s orthopedic ... with total market size rising from 3.28 billion yuan ...
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... at ACG Annual Scientific Meeting -, ORLANDO, ... Inc.) and Forest Laboratories,Inc. (NYSE: FRX ) ... Phase,2b study assessing linaclotide,s safety and efficacy in ... Analysis of the data,indicates that once- daily oral ...
... Randomized Placebo-Controlled Phase II Study Shows ... Overall Survival., MOUNTAIN VIEW, California, October 7 ... from the,therapeutic prostate cancer vaccine candidate PROSTVAC(TM) that had ... the National,Cancer Institute (NCI) in the US., The ...
Cached Medicine Technology:Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4
Lorgnette pinhole occluder...
Double Ended Occluders...
Designed to provide occlusion while permitting observation of the eye. Helpful to determine if only one eye is deviating. Approximately 9 inches long....
Long handle occluders are approximately 9 inches long....
Medicine Products: